The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Rowden, D., Solky, A. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2258 · Cited by 816
Biology of breast cancer in young women
Azim, H. A., & Partridge, A. H. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0427-5 · Cited by 475
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Greer, J. A., Amoyal, N. R., Nisotel, L. E., Fishbein, J. N., MacDonald, J. J., Stagl, J. M., Lennes, I. T., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0405 · Cited by 364
Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors
Irwin, M. L., Cartmel, B., Gross, C. P., Ercolano, E., Li, F., Yao, X., Fiellin, M., Capozza, S., Rothbard, M., Zhou, Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1547 · Cited by 324
Franzoi, M. A., Agostinetto, E., Perachino, M., Mastro, L. D., de Azambuja, E., Vaz-Luís, I., Partridge, A. H., & Lambertini, M. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30666-5 · Cited by 304
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch–Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O. A. M., Azim, H. A., Bianchi-Micheli, G., Cardoso, M. J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 269
Chirgwin, J. H., Giobbie-Hurder, A., Coates, A. S., Price, K. N., Ejlertsen, B., Debled, M., Gelber, R. D., Goldhirsch, A., Smith, I., Rabaglio, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8619 · Cited by 244
An update on the management of breast cancer in Africa
Vanderpuye, V. D. N. K., Grover, S., Hammad, N., Prabhakar, P., Simonds, H. M., Olopade, F., & Stefan, D. C. (2017) · Infectious Agents and Cancer · doi:10.1186/s13027-017-0124-y · Cited by 207
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
Chlebowski, R. T., Kim, J., & Haque, R. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0389 · Cited by 195
Yussof, I., Tahir, N. A. M., Hatah, E., & Shah, N. M. (2022) · The Breast · doi:10.1016/j.breast.2022.01.012 · Cited by 185
Markham, M. J., WACHTER, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C., Galindo, C. R., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 181
Cottu, P. H., D’Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P., Duhoux, F., Lévy, C., Mouret‐Reynier, M., Dalenc, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy448 · Cited by 174
Triple negative breast cancer: looking for the missing link between biology and treatments
Palma, G., Frasci, G., Chirico, A., Esposito, E., Siani, C., Saturnino, C., Arra, C., Ciliberto, G., Giordano, A., & D’Aiuto, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5306 · Cited by 172
Lin, C., Clark, R., Tu, P., Bosworth, H. B., & Zullig, L. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4317-2 · Cited by 160
Kline, R. M., Arora, N., Bradley, C. J., Brauer, E. R., Graves, D. L., Lunsford, N. B., McCabe, M. S., Nasso, S. F., Nekhlyudov, L., Rowland, J. H., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy176 · Cited by 162
Moon, Z., Moss-Morris, R. E., Hunter, M. S., Carlisle, S., & Hughes, L. D. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s126651 · Cited by 155
Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M. A., Láng, I., Gómez, H., Tondini, C. A., Pinotti, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01967 · Cited by 149
Roberts, M. C., Wheeler, S. B., & Reeder-Hayes, K. E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2014.302490 · Cited by 142
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
McCowan, C., Wang, S., Thompson, A. M., Makubate, B., & Petrie, D. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.464 · Cited by 137
Management of breast cancer in very young women
Rosenberg, S. M., & Partridge, A. H. (2015) · The Breast · doi:10.1016/j.breast.2015.07.036 · Cited by 130
Lambert, L. K., Balneaves, L. G., Howard, A. F., & Gotay, C. C. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4561-5 · Cited by 134
Ohnstad, H. O., Borgen, E., Falk, R. S., Lien, T. G., Aaserud, M., Sveli, M., Kyte, J. A., Kristensen, V. N., Geitvik, G. A., Schlichting, E., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0911-9 · Cited by 126
Ruggeri, M., Pagan, E., Bagnardi, V., Bianco, N., Gallerani, E., Buser, K., Giordano, M., Gianni, L., Rabaglio, M., Freschi, A., et al. (2019) · The Breast · doi:10.1016/j.breast.2019.07.001 · Cited by 123
Winn, A. N., Keating, N. L., & Dusetzina, S. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4184 · Cited by 120
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112
Peddie, N., Agnew, S., Crawford, M., Dixon, D. L., Macpherson, I. R., & Fleming, L. (2021) · The Breast · doi:10.1016/j.breast.2021.05.005 · Cited by 112
Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping
Binkhorst, L., Mathijssen, R. H. J., Jager, A., & van Gelder, T. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.01.002 · Cited by 110
Sexual Problems During the First 2 Years of Adjuvant Treatment with Aromatase Inhibitors
Schover, L. R., Baum, G. P., Fuson, L. A., Brewster, A. M., & Melhem‐Bertrandt, A. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12684 · Cited by 116
Stanton, A. L., Petrie, K. J., & Partridge, A. H. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2961-3 · Cited by 109
Thomas, G. A., Cartmel, B., Harrigan, M., Fiellin, M. G., Capozza, S. J., Zhou, Y., Ercolano, E. A., Gross, C. P., Hershman, D. L., Ligibel, J. A., et al. (2016) · Obesity · doi:10.1002/oby.21729 · Cited by 107
Huiart, L., Ferdynus, C., & Giorgi, R. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2422-4 · Cited by 106
Graetz, I., McKillop, C. N., Stepanski, E., Vidal, G. A., Anderson, J. N., & Schwartzberg, L. S. (2018) · Journal of Cancer Survivorship · doi:10.1007/s11764-018-0682-z · Cited by 106
Atema, V., van Leeuwen, M., Kieffer, J. M., Oldenburg, H. S. A., van Beurden, M., Gerritsma, M. A., Kuenen, M. A., Plaisier, P. W., Lopes Cardozo, A. M. F., van Riet, Y. E. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00655 · Cited by 105
Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer
He, W., Fang, F., Varnum, C., Eriksson, M., Hall, P. N., & Czene, K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.3673 · Cited by 108
Martínez-Jáñez, N., Herrera, M., Frías, L., Provencio, M., Pérez-Carrión, R., Díaz, V. D., Morse, M. A., & Crespo, M. C. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1950-0 · Cited by 109
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N. J., Walter, F. M., Donnelly, P., Lavery, B., Morgan, A., Morris, C., & Watson, E. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12601 · Cited by 98
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors
Paranjpe, R., John, G., Trivedi, M. V., & Abughosh, S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05073-z · Cited by 101
Loo, S. Y., Toh, L. P., Xie, W. H., Pathak, E., Tan, W. W. S., Ma, S., Lee, M. Y., Shatishwaran, S., Yeo, J. Z. Z., Yuan, J. X., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2443 · Cited by 94
Hadji, P., Ziller, V., Kyvernitakis, I., Bauer, M. W., Haas, G., Schmidt, N., & Kostev, K. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2417-1 · Cited by 92
Improving Adherence to Oral Cancer Therapy in Clinical Practice
McCue, D. A., Lohr, L., & Pick, A. M. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1399 · Cited by 92
Sheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7367 · Cited by 91
Cahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Chen, Y., Yu, J., Metcalfe, C., Bruyn, T. D., Gelzleichter, T. R., Malhi, V., Pérez-Moreno, P. D., & Wang, X. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1983542 · Cited by 84
Harrow, A., Dryden, R., McCowan, C., Radley, A., Parsons, M., Thompson, A. M., & Wells, M. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005285 · Cited by 87
Ziller, V., Kyvernitakis, I., Knöll, D., Storch, A., Hars, O., & Hadji, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-407 · Cited by 82
Inotai, A., Ágh, T., van Maris, R. F., Erdősi, D., Kovács, S., Kaló, Z., & Senkus, E. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102264 · Cited by 90
Alsabbagh, M. H. D. W., Lemstra, M., Eurich, D., Lix, L. M., Wilson, T. W., Watson, E., & Blackburn, D. F. (2014) · Value in Health · doi:10.1016/j.jval.2013.11.011 · Cited by 82
Baglia, M. L., Lin, I., Cartmel, B., Sanft, T. B., Ligibel, J. A., Hershman, D. L., Harrigan, M., Ferrucci, L. M., Li, F., & Irwin, M. L. (2019) · Cancer · doi:10.1002/cncr.32051 · Cited by 84
Hurtado-de-Mendoza, A., Cabling, M. L., Lobo, T., Dash, C., & Sheppard, V. B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.006 · Cited by 79
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77
Fatores associados à persistência à terapia hormonal em mulheres com câncer de mama
Brito, C., Portela, M. C., & de Vasconcellos, M. T. L. (2014) · Revista de Saúde Pública · doi:10.1590/s0034-8910.2014048004799 · Cited by 79
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Cardoso, F., Parke, S., Brennan, D. J., Briggs, P., Donders, G. G. G., Panay, N., Mashhadi, N. H., Block, M. S., Caetano, C., Francuski, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415566 · Cited by 75
Arem, H. E., Sorkin, M., Cartmel, B., Fiellin, M. G., Capozza, S. J., Harrigan, M., Ercolano, E. A., Zhou, Y., Sanft, T. B., Gross, C. P., et al. (2016) · Journal of Cancer Survivorship · doi:10.1007/s11764-015-0511-6 · Cited by 79
Kadakia, K. C., Snyder, C. F., Kidwell, K., Seewald, N. J., Flockhart, D. A., Skaar, T. C., Desta, Z., Rae, J. M., Otte, J. L., Carpenter, J. S., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0349 · Cited by 76
Bright, E. E., Finkelstein, L. B., Nealis, M. S., Genung, S. R., Wrigley, J., Gu, H. C. J., Schmiege, S. J., & Arch, J. J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00697 · Cited by 74
Vodermaier, A., Linden, W., Rnic, K., Young, S., Ng, A., Ditsch, N. C., & Olson, R. A. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2795-4 · Cited by 73
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy
Kimmick, G., Edmond, S. N., Bosworth, H. B., Peppercorn, J., Marcom, P. K., Blackwell, K., Keefe, F. J., & Shelby, R. A. (2015) · The Breast · doi:10.1016/j.breast.2015.06.010 · Cited by 72
Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship
Bodai, B. I., & Nakata, T. E. (2020) · The Permanente Journal · doi:10.7812/tpp/19.129 · Cited by 73
Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer.
DiBonaventura, M., Copher, R. M., Basurto, E., Faria, C., & Lorenzo, R. (2014) · PubMed Central · Cited by 71
Adherence to hormone therapy among women with breast cancer
Brito, C., Portela, M. C., & de Vasconcellos, M. T. L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-397 · Cited by 74
Toledo, G., Ochoa, C. Y., & Farias, A. J. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05722-4 · Cited by 77
Eliassen, F. M., Blåfjelldal, V., Helland, T., Hjorth, C. F., Hølland, K., Lode, L., Bertelsen, B.-E., Janssen, E. A. M., Mellgren, G., Kvaløy, J. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11122-8 · Cited by 76
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
Binkhorst, L., Mathijssen, R. H. J., van Herk‐Sukel, M. P. P., Bannink, M., Jager, A., Wiemer, E. A. C., & van Gelder, T. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2585-z · Cited by 70
A systematic review of interventions to improve adherence to endocrine therapy
Heiney, S. P., Parker, P. D., Felder, T. M., Adams, S. A., Omofuma, O. O., & Hulett, J. M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5012-7 · Cited by 69
Hadji, P., Jackisch, C., Bolten, W. W., Blettner, M., Hindenburg, H., Klein, P., König, K., Kreienberg, R., Rief, W., Wallwiener, D. R., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt513 · Cited by 70
Hsieh, K., Chen, L., Cheung, K., Chang, C.-S., & Yang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087027 · Cited by 72
The management of adolescents and young adults with cancer
Hughes, N., & Stark, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.001 · Cited by 66
Poortmans, P. M., Arenas, M., & Livi, L. (2016) · The Breast · doi:10.1016/j.breast.2016.07.022 · Cited by 66
Ayres, L. R., Baldoni, A. D. O., Borges, A. P. D. S., & Pereira, L. R. L. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9833-5 · Cited by 65
Ekinci, E., Nathoo, S., Korattyil, T., Vadhariya, A., Zaghloul, H. A., Niravath, P. A., Abughosh, S., & Trivedi, M. V. (2018) · Journal of Cancer Survivorship · doi:10.1007/s11764-017-0674-4 · Cited by 68
Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
Lambert, L. K., Balneaves, L. G., Howard, A. F., Chia, S., & Gotay, C. C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4644-7 · Cited by 67
Anderson, J. N., Graff, J. C., Krukowski, R. A., Schwartzberg, L. S., Vidal, G. A., Waters, T. M., Paladino, A. J., Jones, T. N., Blue, R., Koçak, M., et al. (2020) · Health Communication · doi:10.1080/10410236.2020.1751383 · Cited by 63
Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients
Arriola, K. J., Mason, T. A., Bannon, K. A., Holmes, C. E., Powell, C. L., Horne, K., & O'Regan, R. M. (2014) · Patient Education and Counseling · doi:10.1016/j.pec.2013.12.019 · Cited by 63
Esmaeilzadeh, P., & Sambasivan, M. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0436-2 · Cited by 68
Brett, J., Boulton, M. G., Fenlon, D., Hulbert-Williams, N., Walter, F. M., Donnelly, P., Lavery, B. A., Morgan, A. A., Morris, C., & Watson, E. K. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s145784 · Cited by 68
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors
Sella, T., Poorvu, P. D., Ruddy, K. J., Gelber, S. I., Tamimi, R. M., Peppercorn, J. M., Schapira, L., Borges, V. F., Come, S. E., Partridge, A. H., et al. (2021) · Cancer · doi:10.1002/cncr.33596 · Cited by 62
Clancy, C., Lynch, J., O'Connor, P. M., & Dowling, M. (2019) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2019.101706 · Cited by 66
Liew, J. R., Christensen, A. J., & de Moor, J. S. (2014) · Journal of Cancer Survivorship · doi:10.1007/s11764-014-0374-2 · Cited by 59
Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer
Rosenberg, S. M., Stanton, A. L., Petrie, K. J., & Partridge, A. H. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0007 · Cited by 61
Cahir, C., Dombrowski, S. U., Kelly, C. M., Kennedy, M. J., Bennett, K., & Sharp, L. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2685-x · Cited by 63
Winn, A. N., & Dusetzina, S. B. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4012 · Cited by 57
Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
Rosso, R., D’Alonzo, M., Bounous, V. E., Actis, S., Cipullo, I., Salerno, E., & Biglia, N. (2023) · Current Oncology · doi:10.3390/curroncol30020112 · Cited by 62
Wells, K. J., Pan, T. M., Vázquez‐Otero, C., Ung, D., Ustjanauskas, A. E., Muñoz, D., Laronga, C., Roetzheim, R. G., Goldenstein, M., Carrizosa, C. M., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3229-8 · Cited by 57
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
van Hellemond, I. E. G., Geurts, S. M. E., & Tjan‐Heijnen, V. C. G. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0541-1 · Cited by 57
Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
Chapdelaine, A. G., & Sun, G. (2023) · Biomolecules · doi:10.3390/biom13081207 · Cited by 58
Physical Activity and Breast Cancer: an Opportunity to Improve Outcomes
Peterson, L. L., & Ligibel, J. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0702-1 · Cited by 59
Buszek, S. M., Lin, H. Y., Bedrosian, I., Tamirisa, N., Babiera, G. V., Shen, Y., & Shaitelman, S. F. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.052 · Cited by 55
Eslami, M., Naderian, R., Bahar, A., Babaeizad, A., Gheshlagh, S. R., Oksenych, V., & Tahmasebi, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1559480 · Cited by 57
Wuensch, P. H., Hahne, A., Haidinger, R., Meißler, K., Tenter, B., Stoll, C., Senf, B., & Hübner, J. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1779-z · Cited by 53
Chesney, T. R., Yin, J., Rajaee, N., Tricco, A. C., Fyles, A., Acuña, S. A., & Scheer, A. S. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.02.019 · Cited by 55
Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women
Collin, L. J., Cronin-Fenton, D. P., Ahern, T. P., Goodman, M. G., McCullough, L. E., Waller, L. A., Kjærsgaard, A., Damkier, P., Christiansen, P., Ejlertsen, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3974 · Cited by 55
Androgen receptor: A promising therapeutic target in breast cancer
Vasiliou, S. K., & Diamandis, E. P. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1575643 · Cited by 52
Laroche, F., Perrot, S., Medkour, T., Cottu, P. H., Pierga, J., Lotz, J., Beerblock, K., Tournigand, C., Chauvenet, L., Bouhassira, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187165 · Cited by 52
Brier, M. J., Chambless, D. L., Gross, R., Chen, J., & Mao, J. J. J. (2016) · Cancer · doi:10.1002/cncr.30318 · Cited by 53
Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. L., & Macpherson, I. R. (2022) · The Breast · doi:10.1016/j.breast.2022.04.010 · Cited by 53
Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer
Bright, E. E., Petrie, K. J., Partridge, A. H., & Stanton, A. L. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3871-3 · Cited by 55
Bluethmann, S. M., Murphy, C. C., Tiro, J. A., Mollica, M. A., Vernon, S. W., & Bartholomew, L. K. (2017) · Oncology nursing forum · doi:10.1188/17.onf.e101-e110 · Cited by 50
Self-citationKroenke, C. H. (2018) · Translational Behavioral Medicine · doi:10.1093/tbm/ibx061 · Cited by 50
Wulaningsih, W., Garmo, H., Ahlgren, J., Holmberg, L., Folkvaljon, Y., Wigertz, A., Hemelrijck, M. V., & Lambe, M. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4890-z · Cited by 53
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
